Pacer Advisors Inc. Has $4.34 Million Position in Zoetis Inc (ZTS)

Pacer Advisors Inc. boosted its holdings in Zoetis Inc (NYSE:ZTS) by 17,478.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,067 shares of the company’s stock after acquiring an additional 42,822 shares during the quarter. Pacer Advisors Inc.’s holdings in Zoetis were worth $4,336,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Zoetis by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 35,947,496 shares of the company’s stock valued at $3,291,353,000 after purchasing an additional 293,614 shares during the period. Vanguard Group Inc boosted its stake in shares of Zoetis by 0.8% during the 3rd quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock worth $3,291,353,000 after acquiring an additional 293,614 shares in the last quarter. Oregon Public Employees Retirement Fund raised its position in Zoetis by 9,042.7% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock worth $168,000 after purchasing an additional 14,178,765 shares during the last quarter. Polen Capital Management LLC raised its position in Zoetis by 1.9% in the 4th quarter. Polen Capital Management LLC now owns 9,553,567 shares of the company’s stock worth $817,212,000 after purchasing an additional 178,893 shares during the last quarter. Finally, Capital World Investors raised its position in Zoetis by 12.3% in the 3rd quarter. Capital World Investors now owns 7,277,936 shares of the company’s stock worth $666,368,000 after purchasing an additional 799,515 shares during the last quarter. Hedge funds and other institutional investors own 90.93% of the company’s stock.

Several research firms recently weighed in on ZTS. UBS Group began coverage on shares of Zoetis in a research report on Wednesday, March 20th. They issued a “neutral” rating for the company. Stifel Nicolaus upgraded shares of Zoetis from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $97.00 to $110.00 in a research report on Monday, March 4th. Zacks Investment Research upgraded shares of Zoetis from a “sell” rating to a “hold” rating in a research report on Saturday, February 16th. BMO Capital Markets upped their price objective on shares of Zoetis from $93.00 to $101.00 and gave the company a “market perform” rating in a research report on Monday, February 25th. Finally, SunTrust Banks assumed coverage on shares of Zoetis in a research report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 price objective for the company. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Zoetis currently has an average rating of “Buy” and a consensus target price of $100.57.

In other news, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $101.89, for a total value of $203,780.00. Following the transaction, the insider now owns 30,727 shares of the company’s stock, valued at approximately $3,130,774.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Clinton A. Jr. Lewis sold 6,125 shares of the stock in a transaction on Monday, January 14th. The stock was sold at an average price of $85.21, for a total transaction of $521,911.25. Following the completion of the transaction, the insider now directly owns 48,070 shares in the company, valued at approximately $4,096,044.70. The disclosure for this sale can be found here. Insiders sold a total of 410,334 shares of company stock worth $38,574,260 in the last three months. Insiders own 0.35% of the company’s stock.

Zoetis stock opened at $101.33 on Thursday. The company has a debt-to-equity ratio of 2.95, a quick ratio of 2.46 and a current ratio of 3.60. The company has a market cap of $48.56 billion, a P/E ratio of 32.37, a PEG ratio of 1.84 and a beta of 0.93. Zoetis Inc has a 1-year low of $77.00 and a 1-year high of $103.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 14th. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.02. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.53 billion. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. Zoetis’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.69 EPS. Research analysts expect that Zoetis Inc will post 3.46 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be issued a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Wednesday, April 17th. Zoetis’s payout ratio is 21.09%.

Zoetis declared that its Board of Directors has approved a share buyback program on Wednesday, December 12th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 4.7% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by WKRB News and is the property of of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2019/04/11/pacer-advisors-inc-has-4-34-million-position-in-zoetis-inc-zts.html.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: How to interpret the current ratio

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.